000178057 001__ 178057
000178057 005__ 20240228145641.0
000178057 0247_ $$2doi$$a10.1080/2162402X.2017.1371896
000178057 0247_ $$2pmid$$apmid:29209572
000178057 0247_ $$2pmc$$apmc:PMC5706611
000178057 0247_ $$2ISSN$$a2162-4011
000178057 0247_ $$2ISSN$$a2162-402X
000178057 037__ $$aDKFZ-2021-03066
000178057 041__ $$aEnglish
000178057 082__ $$a610
000178057 1001_ $$aCabo, Mariona$$b0
000178057 245__ $$aTrial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
000178057 260__ $$aAbingdon$$bTaylor & Franics$$c2017
000178057 3367_ $$2DRIVER$$aarticle
000178057 3367_ $$2DataCite$$aOutput Types/Journal article
000178057 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660646078_10248$$xReview Article
000178057 3367_ $$2BibTeX$$aARTICLE
000178057 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178057 3367_ $$00$$2EndNote$$aJournal Article
000178057 500__ $$aPOF Topic: 317
000178057 520__ $$aThe goal of cancer immunotherapy is to establish new or boost pre-existing anticancer immune responses that eradicate malignant cells while generating immunological memory to prevent disease relapse. Over the past few years, immunomodulatory monoclonal antibodies (mAbs) that block co-inhibitory receptors on immune effectors cells - such as cytotoxic T lymphocyte-associated protein 4 (CTLA4), programmed cell death 1 (PDCD1, best known as PD-1) - or their ligands - such as CD274 (best known as PD-L1) - have proven very successful in this sense. As a consequence, many of such immune checkpoint blockers (ICBs) have already entered the clinical practice for various oncological indications. Considerable attention is currently being attracted by a second group of immunomodulatory mAbs, which are conceived to activate co-stimulatory receptors on immune effector cells. Here, we discuss the mechanisms of action of these immunostimulatory mAbs and summarize recent progress in their preclinical and clinical development.
000178057 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000178057 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178057 650_7 $$2Other$$aCD137
000178057 650_7 $$2Other$$aCD40
000178057 650_7 $$2Other$$aGITR
000178057 650_7 $$2Other$$aICOS
000178057 650_7 $$2Other$$aOX40
000178057 650_7 $$2Other$$aPD-1
000178057 7001_ $$0P:(DE-He78)81ae96953d6149e4307057d71a190019$$aOffringa, Rienk$$b1$$udkfz
000178057 7001_ $$aZitvogel, Laurence$$b2
000178057 7001_ $$aKroemer, Guido$$b3
000178057 7001_ $$aMuntasell, Aura$$b4
000178057 7001_ $$aGalluzzi, Lorenzo$$b5
000178057 773__ $$0PERI:(DE-600)2645309-5$$a10.1080/2162402X.2017.1371896$$gVol. 6, no. 12, p. e1371896 -$$n12$$pe1371896 -$$tOncoImmunology$$v6$$x2162-4011$$y2017
000178057 909CO $$ooai:inrepo02.dkfz.de:178057$$pVDB
000178057 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)81ae96953d6149e4307057d71a190019$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000178057 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000178057 9141_ $$y2017
000178057 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOIMMUNOLOGY : 2019$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-01-29
000178057 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOIMMUNOLOGY : 2019$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-29
000178057 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-29
000178057 9201_ $$0I:(DE-He78)G180-20160331$$kG180$$lMolekulare Grundlagen Gastrointestinaler Tumoren$$x0
000178057 980__ $$ajournal
000178057 980__ $$aVDB
000178057 980__ $$aI:(DE-He78)G180-20160331
000178057 980__ $$aUNRESTRICTED